Evidence map›Paper›PMID 27625981›Full record

ArticleSpringerPlus2016

Detection of mesenchymal stem cells senescence by prelamin A accumulation at the nuclear level.

Chiara Bellotti, Cristina Capanni, Giovanna Lattanzi, Davide Donati, Enrico Lucarelli, Serena Duchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Detection of Mesenchymal Stem Cell Aging Using an Integrin Mechano-Probe.Annals of the New York Academy of Sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chiara BellottiOsteoarticular Regeneration Laboratory, 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, Bologna, 40036 Italy ; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.ORCID 0000-0001-9900-7357
Cristina CapanniInstitute of Molecular Genetics - Unit of Bologna, CNR-National Research Council of Italy, Bologna, Italy ; Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopaedic Institute, Bologna, Italy.
Giovanna LattanziInstitute of Molecular Genetics - Unit of Bologna, CNR-National Research Council of Italy, Bologna, Italy ; Laboratory of Musculoskeletal Cell Biology, Rizzoli Orthopaedic Institute, Bologna, Italy.
Davide DonatiOsteoarticular Regeneration Laboratory, 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, Bologna, 40036 Italy ; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Enrico LucarelliOsteoarticular Regeneration Laboratory, 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, Bologna, 40036 Italy.
Serena DuchiOsteoarticular Regeneration Laboratory, 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, Bologna, 40036 Italy ; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman mesenchymal stem cells (MSC), during in vitro expansion, undergo a progressive loss of proliferative potential that leads to the senescent state, associated with a reduction of their "medicinal" properties. This may hampers their efficacy in the treatment of injured tissues. Quality controls on MSC-based cell therapy products should include an assessment of the senescent state. However, a reliable and specific marker is still missing. From studies on lamin-associated disorders, has emerged the correlation between defective lamin A maturation and cellular senescence.

findingsPrimary cultured hMSC lines (n = 3), were analyzed by immunostaining at different life-span stages for the accumulation of prelamin A, along with other markers of cellular senescence. During culture, cells at the last stage of their life span displayed evident signs of senescence consistent with the positivity of SA-β-gal staining. We also observed a significant increase of prelamin A positive cells. Furthermore, we verified that the cells marked by prelamin A were also positive for p21(Waf1) while negative for Ki67.

conclusionsOverall data support that the detection of prelamin A identifies senescent MSC, providing an easy and reliable tool to be use alone or in combination with known senescence markers to screen MSC before their use in clinical applications.

Indexed as

Cell- and tissue-based therapyLamin AMesenchymal stem cellsPrelamin ASenescence

Identifiers

PMID27625981
PMCPMC5001959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.